SeqOne Secures €20M Growth Funding
SeqOne, a Montpellier, France-based AI-driven genomic analysis company focused on personalized medicine, has raised €20 million growth funding round.
The oversubscribed round was led by Supernova Invest, with continued support from Elaia, Omnes, and Mérieux Equity Partners.
Mérieux Equity Partners (MxEP) is an AMF-accredited investment firm specializing in the healthcare sector. With over €1.5 billion in assets under management across two dedicated strategies—Innovation and Buyout—MxEP supports companies ranging from start-ups to established industry leaders.
The company will use the funding to scale international operations, accelerate growth in the U.S. market, and pursue strategic acquisitions to expand capabilities.
SeqOne is a deep-tech company committed to making personalized medicine a reality. Its AI-powered genomic analysis platform provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analyses of genetic data for applications in oncology, rare diseases, and—through recent acquisitions—multi-omics, including pathogen detection. With 140 active lab customers across 22 countries and a projection to process over 110,000 patient analyses in 2025, SeqOne serves a growing global customer base of healthcare providers and biopharmaceutical companies.
Funding Details
Company: SeqOne SAS
Raised: €20.0M
Round: Growth Funding
Funding Date: May 2025
Lead Investor: Supernova Invest
Additional Investors: Elaia, Omnes, Mérieux Equity Partners
Company Website: https://www.seqone.com/
Software Category: Genomic Analysis / AI-Driven Personalized Medicine